Understand the source comparison
Pe-22-28 vs Semax Amidate — Research Applications Comparison
Acute cognitive enhancement studies (≤24 hours) Not suitable. Mechanism requires 14+ days chronic dosing to manifest Highly suitable. Measurable effects within 60–90 minutes post-dose Semax Amidate is the only option for same-day cognitive testing protocols Lo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute cognitive enhancement studies (≤24 hours)
- Not suitable. Mechanism requires 14+ days chronic dosing to manifest
- Highly suitable. Measurable effects within 60–90 minutes post-dose
- Semax Amidate is the only option for same-day cognitive testing protocols
- Long-term neuroplasticity research (28+ days)
- Optimal. Sustained BDNF elevation promotes dendritic growth and synaptogenesis
- Suboptimal. Acute neurotransmitter modulation does not drive structural plasticity
- Pe-22-28 demonstrates superior neurogenic effects in chronic paradigms
- Memory consolidation assays
- Effective when administered daily throughout training phase (14–21 days)
- Effective when administered 30–60 minutes pre-training session
- Both work but through different mechanisms. Pe-22-28 enhances encoding capacity, Semax Amidate enhances retrieval performance
- Neuroprotection after ischemic injury
- Limited evidence. TREK-1 inhibition may reduce excitotoxicity but lacks robust preclinical validation
- Strong evidence. Multiple studies show reduced infarct volume and improved functional recovery when administered within 6 hours post-injury
- Semax Amidate has superior published evidence for acute neuroprotection
- Cost per 28-day research protocol (rodent model, n=10)
- Approximately $180–220 depending on dosing tier
- Approximately $240–280 depending on dosing tier
- Pe-22-28 is more cost-effective for chronic studies; Semax Amidate is more expensive but necessary for acute paradigms